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Abstract: To search for favourable prognostic factors in carcinosarcoma (CS) on the basis of clinical, morpho-
logical and immunocytochemical data, while simultaneously considering the histogenesis of this neoplasm. Thir-
ty two uterine CS patients were analysed based on clinical and morphological data. In addition, each specimen
was examined by immunohistochemistry with antibodies characteristic for relevant types of cells and tissues.
The presence of both carcinomatous and sarcomatous patterns was observed in all tumours. Among carcinoma-
tous patterns, endometrioid carcinoma was the commonest, while serous, clear cell, and undifferentiated carci-
nomas were less common. Among sarcomatous patterns, endometrioid sarcomas represented the largest group,
while leiomyosarcomas, chondrosarcomas, fibrosarcomas, osteosarcomas, and rhabdosarcomas were rarely ob-
served. Mitotic activity was evidently higher in carcinomas. In seven cases, the expression of both cytokeratin
and vimentin was noted in cells of carcinomatous patterns. We found that an early diagnosis (stage I-II) and an
initially aggressive surgical cytoreduction were favourable prognostic factors in CS. Furthermore, the presence
of cytokeratin-vimentin positive cells in carcinomatous patterns suggests sarcomatous metaplasia of adenocarci-
noma. However, the prognostic value of various histological structures of carcinosarcomas could not be identi-
fied. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 4, 513–518)
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Introduction
Carcinosarcomas (CS), also known historically as
malignant mixed mesodermal tumours, are consid-
ered to be one of the most aggressive uterine cancers
[1–3]. They are most commonly composed of carci-
nomatous components and malignant mesenchymal
components. Because of their complicated histogen-
esis, there are numerous uterine carcinosarcoma clas-
sification hypotheses, and debate continues as to
whether CS is monoclonal or biclonal. However, most
authors agree with the ‘combination hypothesis’,
which states that CS originates from high-grade car-
cinoma with sarcomatous differentiation. The ‘con-
version hypothesis’ states that CS is derived from a
single stem cell population which is multipotent or
has a potential for metaplastic transformation. On the
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contrary, the ‘collision hypothesis’ assumes that
a neoplastic tumour develops from two separate po-
pulations of stem cells [3–5].
In the latest edition (2009) of the ‘TNM Classifi-
cation of Malignant Tumours’, the same classification
was applied for CS as for uterine carcinoma [6]. Based
on molecular, epidemiological, genetic and histo-
pathological data, most authors support the mono-
clonal hypothesis, which states that primary malig-
nant epithelial cells are presumably subjected to mes-
enchymal metaplasia [3–5], thus, the terms ‘sarcoma-
toid carcinoma of the uterus’ or ‘metaplastic
carcinoma’ have been proposed for this neoplasm [3].
The aim of our study was to assess the disease course
based on the age of the patient, surgical staging, surgi-
cal treatment approach, chemotherapy and radiother-
apy. Additionally, we performed histopathological anal-
ysis based on haematoxylin and eosin (HE) staining
and immunohistochemical staining of histological sec-
tions. This assessment included tumour size, stage ac-
cording to FIGO classification, type of morphological
patterns in primary tumours, and metastases. We at-
tempted to separate the predictive factors based on
clinicopathologic data and to look into issues surround-
ing the histogenesis of uterine carcinosarcoma.
Material and methods
Out of 37 women diagnosed with carcinosarcoma and treat-
ed at our hospital, five had the primary tumour in their ova-
ries. The remaining 32 patients had developed the neoplasm
in the uterus. Only uterine carcinosarcoma patients were
further analysed. The youngest patient diagnosed with car-
cinosarcoma of the uterus was 33 years old, and the oldest
was 82. The average age of patients at diagnosis was
65.7 years. In 24 patients, the disease was diagnosed be-
tween 2001 and 2006, whereas in eight patients it was diag-
nosed between 2008 and 2009.
Archival paraffin blocks were sectioned at the Depart-
ment of Pathomorphology at the Gynaecology and Obstet-
rics Clinical Hospital in Poznan. Histopathological analysis
was based on H&E staining and immunohistochemical stain-
ing (Table 1). Immunostaining was performed using the
DAKO LSAB+ System HRP technique. In brief, epitope
retrieval was performed by heating at 95–99°C in pH 6.1
modified citrate buffer, Dako Target Retrieval Solution,
using a water bath. Next, endogenous peroxidase activity
was blocked with 3% H2O2 for five minutes. After washing
with TBSi buffer solution, the tissue sections were incubat-
ed with the primary antibody for 30 minutes and then washed
again. Next, the sections were incubated with a biotinylated
secondary antibody, from DakoCytomation LSAB+System-
HRP, for 30 minutes and washed. Then, the tissue sections
were stained with streptavidin/peroxidase complex, from Da-
koCytomation LSAB+System-HRP, for 30 minutes and again
washed. 3,3’-diaminobenzidine tetrahydrochloride (DAB) so-
lution was applied to tissue sections for ten minutes. Then the
tissue sections were again washed, counterstained with hae-
matoxylin, dehydrated and mounted in balsam.
Immunopositive staining observed in at least 10% of cells
was defined as a positive result. The presence of an immu-
nopositive reaction in 10% of cells was assessed as 1+; reac-
tion in 50% of cells was assessed as 2+; and reaction in
more than 60% of cells was assessed as 3+. Negative con-
trols were prepared by omitting the primary antibody. Pos-
itive controls, for the assessment of CD117 expression, were
prepared from tissue sections of gastrointestinal stromal
tumour (GIST), which stains positively for CD117.
Results
Clinical characteristics of the patients
All 32 patients with a diagnosis of carcinosarcoma of
the uterus underwent total hysterectomy with bilat-
eral salpingo-oopherectomy and omentectomy. Only
Table 1. Primary antibodies and their respective immunophenotypes
Antibodies* Form Dilution Immunophenotype
CD10 Monoclonal 1:80 Endometrial stromal sarcoma
CD117** Polyclonal 1:500 Tyrosine kinase transmembrane receptor
Vimentin Monoclonal 1:150 Mesenchymal cells
AE1/AE3 cytokeratin Monoclonal Pre-diluted by the manufacturer Epithelial cells
Desmin Monoclonal 1:100 Leiomyosarcoma
Progesterone receptor (PR) Monoclonal Pre-diluted by the manufacturer Well or moderately
Oestrogen receptor (OR) differentiated endometrioid cancer
*All primary antibodies were from DakoCytomation, Poland; **paraffin sections of a gastrointestinal stromal tumour (GIST) positive for CD117
were used as a positive control
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one of the patients with stage I advancement of car-
cinosarcoma also had pelvic lymphadenectomy. Of
these, 25 patients were classified as either stage I or
II. The remaining seven patients were classified as
stage III or IV. In the 25 stage I and II patients, the
neoplasms were limited to the uterus. Peritoneal
washings obtained from 16 of the 25 were negative
for cancer cells. However, in peritoneal washings ob-
tained from the seven patients diagnosed with either
stage III or IV, cancer cells were identified. Five of
the seven patients had neoplastic infiltration of the
ovaries, oviducts, and omentum, while the remaining
two also had neoplastic infiltration of the peritone-
um and appendix. All patients were subjected to ra-
diation therapy. In addition, patients with cancer stage
II, III or IV received a combination chemotherapy
regimen. Chemotherapy treatment consisted of plat-
inum, DNA alkylating agents (e.g. ifosfamide), and
taxanes that inhibit mitotic activity. Two patients re-
ceived a combination chemotherapy regimen of CAE-
LYX and CYVADIC. Patients diagnosed with stage
III and IV cancer died during the first, second or third
year following the initial diagnosis of uterine carci-
nosarcoma. The deaths were primarily due to either
lung metastasis or kidney insufficiency.
Histological structure of uterine carcinosarcomas
 Based on H&E and immunohistochemical stain-
ing, various neoplastic patterns were observed, which
are presented in Table 2.
Among carcinomatous components, endometrio-
id carcinomas were most abundant: they were ob-
served in 16 (50%) specimens. Clear cell carcinomas
were observed in four (13%) specimens, serous car-
cinomas were observed in seven (22%) specimens,
squamous cell carcinomas were observed in two (6%)
specimens, and undifferentiated were observed in
three (9%) specimens. We cannot exclude the possi-
bility that squamous patterns originated from squa-
mous metaplasia of endometrioid carcinoma. Most
tumour masses (19 of 32) presented mainly a glandu-
lar pattern. In the remaining 13, the glandular pat-
tern comprised a smaller portion of the tumour mass.
In four of the 13 tumour masses, only single glandu-
lar cells were observed. Most of the carcinomas were
either poorly (G3) or moderately (G2) differentiated
(22). In seven analysed neoplasms, the expression of
vimentin was observed in an endometrioid glandular
pattern and these cells were also positive for cytoker-
atin AE1/AE3 (Figures 1, 2). Patterns showed proges-
terone receptor (PR) and oestrogen receptor (OR)
expression scored from 0 to 3+. More differentiated
cancers demonstrated PR and OR expression of 2+
to 3+, while poorly differentiated showed PR and OR
expression of 0 to 1+. Surprisingly, we did not ob-
serve an immunopositive reaction for CD117 in any
of the analysed tumours.
The largest group among sarcomatous elements (16)
was represented by stromal sarcoma. Most of them
(60%) demonstrated CD10 positive expression. The
remaining sarcomas observed, in order of decreasing
number, were leiomyosarcoma (desmin positive), chon-
drosarcoma, fibrosarcoma, osteosarcoma, rhabdomyo-
sarcoma and malignant mesenchymoma. In clinicomor-
phological analysis, we did not identify the prognostic
value of histological structures of carcinosarcomas.
Table 2. Histopathological characteristics of carcinosarcomas
Number of cases
FIGO stage
 I 16
 II 9
III and IV 7
Types of glandular pattern
Endometrial carcinoma 16
Clear cell carcinoma 4
Serous carcinoma 7
Squamous cell carcinoma 2
Undifferentiated carcinoma 3
Carcinomatous v. sarcomatous component
Carcinomatous patterns predominantly 19
Sarcomatous patterns predominantly 13 (4/13 tumours
showed single
distribution of cells)
Grade of cancer differentiation
1° 7
2° 6
3° 19
Mitotic activity  > 10/10 HPF
(High Power Field)
Types of sarcomatous pattern
Stromal sarcoma 12
Leiomyosarcoma 8
Rhabdomyosarcoma 2
Chondrosarcoma 8
Osteosarcoma 3
Fibrosarcoma 4
Malignant mesenchymoma 2
Mitotic activity < 10/10HPF
Histological pattern in metastases
Glandular pattern only 2
Carcinomatous pattern and small
admixture of sarcomatous pattern 3
predominantly sarcomatous pattern 2
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In metastases, a carcinomatous pattern was ob-
served in only two patients (Figure 3), a carcinoma-
tous pattern admixed with a sarcomatous pattern was
observed in three patients, and an almost exclusively
sarcomatous pattern was observed in two patients.
Discussion
Carcinosarcomas (CS) are tumours where both mes-
enchymal and epithelial components are of malignant
Figure 1. Carcinomatous pattern in carcinosarcoma;
immunopositive for cytokeratin (A) and vimentin (B),
and immunonegative reaction for vimentin (C). Original
magnification 200 ×
A
B
Figure 2. Poorly differentiated carcinosarcoma, immunopo-
sitive for cytokeratin (A) and vimentin (B). 200 ×
Figure 3. CS metastases to ovary: clear cell pattern. HE
staining, 200 ×
C
A
B
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nature and are considered one of the most aggressive
uterine cancers. Uterine carcinosarcomas are rare.
Although, in relation to carcinoma, carcinosarcoma
develops in older women, their risk factors are simi-
lar. CS incidence increases after pelvic irradiation and
exposure to exogenous oestrogens. Since adipose tis-
sue is a source of oestrogen, increased CS incidence
may be attributable to obesity [3,9]. Furthermore,
tamoxifen administered for breast cancer treatment
is associated with a 2–3-fold increase in the risk of CS
incidence [3, 8].
In carcinosarcomas, among carcinomatous pat-
terns, most commonly listed are endometrioid can-
cers, while among sarcomatous patterns, commonly
observed are stromal sarcomas, and less commonly
leiomyosarcomas and chondrosarcomas [3, 4, 11].
Uterine cancer patterns, when considered sepa-
rately, have different prognoses. Five-year survival for
women diagnosed with type I cancer reaches 90%,
whereas in those diagnosed with type II cancer, it
is between 50% and 60%, and in those diagnosed
with carcinosarcoma it is between 33% and 39% [4,
10–13]. Five-year survival for leiomyosarcoma is assessed
to be between 15% and 25%, but for stage I and II it
is assessed to be between 40% and 70% [14]. Bosquet
et al. examined 121 patients with carcinosarcoma of
the uterus treated with adjuvant chemotherapy fol-
lowing surgical resection. They found that the five-
year survival for stage I and II was 59%, for stage III
it was 22%, and for stage IV it was 9% [4]. Yamade et
al. [13] demonstrated five-year survival of 74% in
patients with CS limited to the uterus; however,
in the group of patients with CS extension beyond
the uterus, five-year survival was only 24%. In our CS
series, seven of the 32 patients diagnosed with stage
III and IV cancer died during the first, second or third
year following the initial diagnosis of uterine carci-
nosarcoma. According to some authors, radiation
therapy does not influence the survival rate of patients
diagnosed with carcinosarcoma [13]. Most studies
available in the literature are based on small groups
of patients, so that conclusions drawn from them may
not always be reliable. Comparing the results of treat-
ment with carcinosarcoma morphological patterns, we
were unable to find morphological structures which
could potentially serve as prognostic markers.
Literature data [4, 15] draws attention to the car-
cinomatous pattern’s higher mitotic activity, higher
proliferation, and metastatic capabilities compared
to the sarcomatous pattern. Our observation was con-
sistent with the studies referenced above [4, 15], since
we also observed higher mitotic activity of the carci-
nomatous pattern than of the sarcomatous pattern,
and glandular metastases to ovaries in two patients.
Carcinosarcoma metastases to other organs most
commonly derive from the carcinomatous pattern [3,
4, 15, 18]. It is difficult to explain which factors deter-
mine the higher activity of carcinomatous pattern.
Several previous genetic studies have emphasised that
in both carcinosarcoma pattern types chromosomal
aberrations were similar, in that they commonly in-
volved loss of heterozygoticity and mutations in p53,
K-ras, C-myc and WT-1 genes [3, 20, 21]. The genetic
similarity between the two neoplastic components
serves as evidence for the monoclonal origin of carci-
nosarcoma.
It is worth noting that, in our immunohistochem-
ical studies, cytoplasm of cells in carcinomatous com-
ponent was positive for vimentin in 22% of analysed
tumours. Concurrently, these cells were also positive
for cytokeratin (Figures 1, 2). Based on these results,
we speculate that these kinds of cytokeratin-vimen-
tin positive cancer cells may be more easily subjected
to metaplasia in spindle-shaped cells forming sarco-
matous patterns with simultaneous mutations on dif-
ferent metabolic levels.
Generally, the treatment employed in our centre
was consistent with that presented in the literature.
First, treatment consisted of total hysterectomy with
bilateral salpingo-oophorectomy, omentectomy and
peritoneal lavage. The mainstay of treatment is radi-
ation therapy, followed by chemotherapy. Unfortu-
nately, according to the literature, CS are not very
sensitive to either chemotherapy or radiation thera-
py [4, 10, 11]. Numerous studies have recently
emerged in which authors have applied Gleevec treat-
ment [16, 17]. Gleevec is a tyrosine kinase inhibitor
which inhibits proliferation of neoplastic cells and
induces apoptosis [16]. The application of Gleevec is
only justifiable in cases of immunopositive reactions
of carcinosarcoma to CD117. This cancer drug is well
tolerated by patients, but demonstrates minimal ac-
tivity when used as monotherapy [16]. However, in
our series of 32 CS patients, we could not demon-
strate in any specimen, in either carcinomatous or
sarcomatous pattern, an immunopositive reaction
when tested for products of c-kit gene specific for
CD117. This contradicts other studies in which im-
munopositive reactions with CD117 antibodies in CS
have been reported [16, 17].
The problem of lymphadenectomy in cases of CS
of the uterus has not yet been conclusively resolved.
It is accepted that while carcinomas migrate mainly
via the lymphatic system, most sarcomas spread via
the vascular system, predominantly to the abdominal
cavity and lungs. In our CS series, only one of the
32 patients had pelvic lymphadenectomy. Randomised
studies of endometrial cancers have neither demon-
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strated longer survival rates nor later metastases in
women who underwent lymphadenectomy compared
to those who did not [22, 23]. In patients with uterine
wall infiltration greater than 1/2 (Ib stage), Park et al.
found that 32% of patients had metastases in lymph
nodes [19], while Bitterman et al. found metastases
mainly in lymphatic ducts of ovaries, fallopian tubes
and omentum [15]. The authors of these studies do
not recommend routine lymphadenectomy as part of
endometrial cancer treatment. However, the bene-
fits of lymphadenectomy in the treatment of CS are
still open to discussion.
In conclusion, cytokeratin-vimentin positive cells
in adenocarcinoma suggest either the possibility of
sarcomatous metaplasia of adenocarcinoma, or
a mesenchymal component arising from stem cell
transformation giving rise to different cell lines. In
this study, we did not find a prognostic value of histo-
logical structures of carcinosarcomas of the uterus.
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